Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

mRNA expression of drug metabolism enzymes and transporter genes at birth using human umbilical cord blood.

Neyro V, Elie V, Médard Y, Jacqz-Aigrain E.

Fundam Clin Pharmacol. 2018 Aug;32(4):422-435. doi: 10.1111/fcp.12357. Epub 2018 Mar 13.

PMID:
29436076
2.

Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.

Adam de Beaumais T, Fakhoury M, Medard Y, Azougagh S, Zhang D, Yakouben K, Jacqz-Aigrain E.

Br J Clin Pharmacol. 2011 Apr;71(4):575-84. doi: 10.1111/j.1365-2125.2010.03867.x.

3.

Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants?

Durrmeyer X, Hovhannisyan S, Médard Y, Jacqz-Aigrain E, Decobert F, Barre J, Alberti C, Aujard Y, Danan C, Baud O.

PLoS One. 2010 Aug 23;5(8):e12329. doi: 10.1371/journal.pone.0012329.

4.

[Therapeutic drug monitoring of 6-thioguanine nucleotides in paediatric acute lymphoblastic leukaemia: interest and limits].

Fakhoury M, de Beaumais T, Médard Y, Jacqz-Aigrain E; Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique.

Therapie. 2010 May-Jun;65(3):187-93. doi: 10.2515/therapie/2010031. Epub 2010 Aug 11. Review. French.

PMID:
20699069
5.

Suivi thérapeutique pharmacologique des 6-thioguanine nucléotides dans les leucémies aigues lymphoblastiques de l'enfant : intérêt et limites.

Fakhoury M, Jacqz-Aigrain E; pour le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et Thérapeutique, de Beaumais T, Médard Y.

Therapie. 2010 May-Jun;65(3):187-93. doi: 10.2515/therapie/2010031. French.

PMID:
27392985
6.

mRNA expression of MDR1 and major metabolising enzymes in human fetal tissues.

Fakhoury M, de Beaumais T, Guimiot F, Azougagh S, Elie V, Medard Y, Delezoide AL, Jacqz-Aigrain E.

Drug Metab Pharmacokinet. 2009;24(6):529-36.

7.

The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.

Adam de Beaumais T, Dervieux T, Fakhoury M, Medard Y, Azougagh S, Zhang D, Yakouben K, Jacqz-Aigrain E.

Cancer Chemother Pharmacol. 2010 Sep;66(4):653-8. doi: 10.1007/s00280-009-1205-4. Epub 2009 Dec 23.

PMID:
20033410
8.

Characterization of a novel TPMT mutation associated with azathioprine-induced myelosuppression.

de Beaumais TA, Fakhoury M, Pigneur B, Viola S, Medard Y, Broly F, Jacqz-Aigrain E.

Br J Clin Pharmacol. 2009 Nov;68(5):770-2. doi: 10.1111/j.1365-2125.2009.03439.x. No abstract available.

9.

Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?

Fakhoury M, Andreu-Gallien J, Mahr A, Medard Y, Azougagh S, Vilmer E, Jacqz-Aigrain E.

J Clin Pharm Ther. 2007 Dec;32(6):633-9.

PMID:
18021342
10.

Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.

Fakhoury M, Lecordier J, Medard Y, Peuchmaur M, Jacqz-Agrain E.

Inflamm Bowel Dis. 2006 Aug;12(8):745-9.

PMID:
16917230
11.

Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age.

Fakhoury M, Litalien C, Medard Y, Cavé H, Ezzahir N, Peuchmaur M, Jacqz-Aigrain E.

Drug Metab Dispos. 2005 Nov;33(11):1603-7. Epub 2005 Jul 27.

PMID:
16049125
12.

Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age.

Ganiere-Monteil C, Medard Y, Lejus C, Bruneau B, Pineau A, Fenneteau O, Bourin M, Jacqz-Aigrain E.

Eur J Clin Pharmacol. 2004 Apr;60(2):89-96. Epub 2004 Mar 12.

PMID:
15022030
13.

Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.

Dervieux T, Médard Y, Verpillat P, Guigonis V, Duval M, Lescoeur B, Suciu S, Vilmer E, Jacqz-Aigrain E.

Leukemia. 2001 Nov;15(11):1706-12.

14.

Monitoring azathioprine therapy in pediatric renal transplant patients with red blood cell thiopurine methyltransferase.

Dervieux T, Médard Y, Baudouin V, Maisin A, Zhang D, Loirat C, Jacqz-Aigrain E.

Transplant Proc. 2000 Mar;32(2):361-3. No abstract available.

PMID:
10715440
15.

Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine.

Dervieux T, Médard Y, Baudouin V, Maisin A, Zhang D, Broly F, Loirat C, Jacqz-Aigrain E.

Br J Clin Pharmacol. 1999 Dec;48(6):793-800.

16.

High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol.

Quernin MH, Poonkuzhali B, Médard Y, Dennison D, Srivastava A, Krishnamoorthy R, Chandy M, Jacqz-Aigrain E.

J Chromatogr B Biomed Sci Appl. 1999 Jan 8;721(1):147-52.

PMID:
10027646
17.

In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans.

Yaïch M, Popon M, Médard Y, Aigrain EJ.

Pharmacogenetics. 1998 Oct;8(5):449-51.

PMID:
9825837
18.

Thiopurine methyltransferase activity: new high-performance liquid chromatographic assay conditions.

Medard Y, Nafa S, Jacqz-Aigrain E.

J Chromatogr B Biomed Sci Appl. 1997 Oct 24;700(1-2):275-7.

PMID:
9390740
19.

Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia.

Jacqz-Aigrain E, Nafa S, Médard Y, Bessa E, Lescoeur B, Vilmer E.

Eur J Clin Pharmacol. 1997;53(1):71-4.

PMID:
9349933
20.

Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors.

Jacqz-Aigrain E, Bessa E, Medard Y, Mircheva Y, Vilmer E.

Br J Clin Pharmacol. 1994 Jul;38(1):1-8.

Supplemental Content

Loading ...
Support Center